Summit Therapeutics Inc (SMMT)
19.00
+0.58
(+3.15%)
USD |
NASDAQ |
Nov 22, 16:00
19.02
+0.02
(+0.11%)
After-Hours: 20:00
Summit Therapeutics Enterprise Value: 13.55B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 13.55B |
| November 21, 2024 | 13.12B |
| November 20, 2024 | 13.27B |
| November 19, 2024 | 14.29B |
| November 18, 2024 | 13.53B |
| November 15, 2024 | 13.04B |
| November 14, 2024 | 13.88B |
| November 13, 2024 | 13.90B |
| November 12, 2024 | 14.85B |
| November 11, 2024 | 15.59B |
| November 08, 2024 | 15.33B |
| November 07, 2024 | 15.10B |
| November 06, 2024 | 14.94B |
| November 05, 2024 | 14.57B |
| November 04, 2024 | 14.26B |
| November 01, 2024 | 13.54B |
| October 31, 2024 | 13.25B |
| October 30, 2024 | 13.29B |
| October 29, 2024 | 15.64B |
| October 28, 2024 | 15.94B |
| October 25, 2024 | 15.22B |
| October 24, 2024 | 13.89B |
| October 23, 2024 | 14.31B |
| October 22, 2024 | 14.71B |
| October 21, 2024 | 14.65B |
| Date | Value |
|---|---|
| October 18, 2024 | 15.17B |
| October 17, 2024 | 15.44B |
| October 16, 2024 | 16.83B |
| October 15, 2024 | 15.64B |
| October 14, 2024 | 14.46B |
| October 11, 2024 | 14.24B |
| October 10, 2024 | 13.25B |
| October 09, 2024 | 13.47B |
| October 08, 2024 | 14.05B |
| October 07, 2024 | 13.48B |
| October 04, 2024 | 13.61B |
| October 03, 2024 | 13.25B |
| October 02, 2024 | 13.94B |
| October 01, 2024 | 14.35B |
| September 30, 2024 | 15.68B |
| September 27, 2024 | 15.12B |
| September 26, 2024 | 16.54B |
| September 25, 2024 | 16.41B |
| September 24, 2024 | 17.41B |
| September 23, 2024 | 15.88B |
| September 20, 2024 | 17.70B |
| September 19, 2024 | 16.79B |
| September 18, 2024 | 17.82B |
| September 17, 2024 | 19.04B |
| September 16, 2024 | 21.44B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
14.95M
Minimum
Dec 01 2022
23.24B
Maximum
Sep 13 2024
1.676B
Average
456.66M
Median
Enterprise Value Benchmarks
| Merck & Co Inc | 274.49B |
| Terns Pharmaceuticals Inc | 119.02M |
| Instil Bio Inc | 132.47M |
| Viking Therapeutics Inc | 4.930B |
| Moderna Inc | 8.953B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.25M |
| Total Expenses (Quarterly) | 58.38M |
| EPS Diluted (Quarterly) | -0.08 |
| Earnings Yield | -1.26% |
| Normalized Earnings Yield | -3.165 |